Zacks Research Has Pessimistic View of Masimo Q2 Earnings

Masimo Corporation (NASDAQ:MASI) – Equities researchers at Zacks Research decreased their Q2 2026 earnings per share (EPS) estimates for shares of Masimo in a note issued to investors on Tuesday, November 25th. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $1.23 per share for the quarter, down from their previous estimate of $1.33. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share.

A number of other equities research analysts have also recently issued reports on MASI. Wells Fargo & Company dropped their target price on shares of Masimo from $190.00 to $187.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Piper Sandler upped their price objective on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. BTIG Research reaffirmed a “buy” rating and set a $198.00 price objective on shares of Masimo in a report on Monday. Bank of America assumed coverage on shares of Masimo in a research note on Monday, November 17th. They issued a “neutral” rating and a $162.00 target price for the company. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Masimo has a consensus rating of “Hold” and a consensus price target of $188.40.

Masimo Stock Down 1.7%

Shares of NASDAQ:MASI opened at $143.96 on Wednesday. Masimo has a 52 week low of $133.70 and a 52 week high of $194.88. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The company’s fifty day moving average is $145.71 and its 200-day moving average is $152.58. The company has a market capitalization of $7.73 billion, a PE ratio of -16.90 and a beta of 1.28.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The business had revenue of $617.00 million for the quarter.

Institutional Investors Weigh In On Masimo

Institutional investors and hedge funds have recently made changes to their positions in the company. Coldstream Capital Management Inc. boosted its holdings in Masimo by 17.2% in the third quarter. Coldstream Capital Management Inc. now owns 2,668 shares of the medical equipment provider’s stock valued at $394,000 after acquiring an additional 391 shares during the last quarter. Danske Bank A S acquired a new position in Masimo during the 3rd quarter valued at about $59,000. Advisory Services Network LLC acquired a new position in Masimo during the 3rd quarter valued at about $46,000. CANADA LIFE ASSURANCE Co boosted its stake in shares of Masimo by 3.8% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 27,120 shares of the medical equipment provider’s stock valued at $3,871,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Masimo during the 3rd quarter worth approximately $1,477,000. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.